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Genetic susceptibility to infectious diseases: big is beautiful, 
but will bigger be even better? 
David Burgner, Sarra E Jamieson, Jenefer M Blackwell
Genetic epidemiology, including twin studies, provides robust evidence that genetic variation in human populations 
contributes to susceptibility to infectious disease. One of the major limitations of studies that attempt to identify the 
genes and mechanisms that underlie this susceptibility has been lack of power caused by small sample size. With the 
development of novel technologies, burgeoning information on the human genome, the HapMap project, and human 
genetic diversity, we are at the beginning of a new era in the study of the genetics of complex diseases. This review 
looks afresh at the epidemiological evidence that supports a role for genetics in susceptibility to infectious disease, 
examines the somewhat limited achievements to date, and discusses current advances in methodology and technology 
that will potentially lead to translational data in the future. 
Introduction
Infection is one of the leading causes of human mortality 
and morbidity, with much of the burden falling on 
children.1 Infectious diseases are a major selective 
pressure,2–5 and the genes involved in the immune response 
are the most numerous and diverse in the human genome,6 
indicating the evolutionary advantages of a varied 
immunological response to a wide range of infectious 
pathogens.7 This is most obvious at the HLA loci,8 the 
prototypical candidate genetic region for infectious disease 
susceptibility. For example, individuals in whom all class II 
HLA alleles are heterozygous are more likely to clear 
hepatitis B infection,9 and those with heterozygous class I 
alleles progress from HIV to an AIDS-deﬁ ning illness 
more slowly and have lower mortality.10 The converse 
scenario, increased HLA homozygosity, may contribute to 
the increased susceptibility to infection in genetically 
isolated populations.11
There is huge variation in the individual outcomes that 
follow exposure to potentially life-threatening pathogens, 
and this diﬀ erential susceptibility partly shows the 
functional genetic diversity of the immune response. 
Here we provide an overview of human genetic 
susceptibility in infectious diseases, review the supporting 
epidemiological evidence, discuss current methodological 
and technological issues, and highlight the somewhat 
limited achievements to date, especially those that have 
increased our understanding of outcome and treatment 
response for speciﬁ c infectious diseases. 
One gene…or many?
Susceptibility to infection and many other human diseases 
(including diabetes and ischaemic heart disease) arises 
from the complex interaction of environmental and host 
genetic factors. In general, many genetic loci make modest 
contributions to human disease susceptibility (ie, they are 
genetically complex), and most of the focus in the ﬁ eld has 
been on identifying these loci and their eﬀ ects in infection 
and in other conditions. However, there are many single-
gene (Mendelian) disorders aﬀ ecting immune function, 
with over 300 primary immunodeﬁ ciencies reported. 
Although often rare, these profound immunodeﬁ ciencies 
stem from major functional aberrations at single genes 
and can be highly informative about immunological 
mechanisms and protection against speciﬁ c infections.12,13 
There are also important examples of more common 
single-gene disorders that markedly inﬂ uence infection-
speciﬁ c susceptibility; the best known is the protection 
aﬀ orded by sickle cell heterozygosity against falciparum 
malaria.14 A variant in the Duﬀ y antigen gene promoter, 
which results in lack of erythrocyte surface expression, 
prevents binding by Plasmodium vivax, and is therefore 
protective.15,16 More recently, a genetic variant that 
determines blood group secretor status has been shown to 
mediate susceptibility to Norwalk virus,17 and also to aﬀ ect 
HIV progression independently of other chemokine 
variants.18 
Hype and hyperbole
There has been substantial expectation that an increased 
understanding of the genetic determinants of diﬀ erential 
susceptibility and outcome would be rapidly translated 
into novel therapies and preventative interventions. 
Much of this expectation has yet to be realised, partly 
because of the methodological limitations of earlier 
studies and a tendency to examine individual genes in 
isolation and without consideration of their genetic and 
environmental milieu. Thus many reported genetic 
associations have not been replicated in subsequent 
studies.19 Understandably, some scepticism exists as to 
how much a genetic epidemiological approach can 
actually reveal about the genetic basis of complex 
diseases.20 However, there have been many recent 
advances in technology and—more latterly—its 
application; such studies have identiﬁ ed important 
protective and pathogenic pathways, and have led to 
individually targeted anti-infective therapies. Hopefully, 
we are entering an era in which well designed studies 
will begin to deliver robust genetic data and many more 
opportunities for translation into better treatments. 
Epidemiological evidence
The idea that human genetics may contribute to our 
understanding of the susceptibility to infectious 
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diseases is not new. As early as the 18th century, 
diﬀ erential susceptibility to infection was suggested to 
be a characteristic of the host, and diseases such as 
tuberculosis and leprosy were believed to be inherited 
defects.21 Infectious diseases, like other phenotypes, 
may exhibit familial aggregation: a greater frequency of 
the disease in relatives of infected individuals compared 
with relatives of those without disease. Studies of 
familial aggregation can therefore investigate the 
importance of shared determinants, both environmental 
and genetic, in disease susceptibility. They usually use a 
form of the recurrence risk ratio, essentially the ratio of 
prevalence in the relatives of the index case to the 
prevalence in the general population. It is important in 
such studies that the disease phenotype is carefully 
deﬁ ned, particularly in the context of infectious 
diseases. Interpretation of recurrence risk is more 
straightforward if the phenotype is a binary or 
dichotomous trait (eg, the presence or absence of 
meningococcal septicaemia) than a qualitative range of 
clinical phenotypes, which may be less consistent (eg, 
measures of severity of infection determined by 
treatment interventions). Familial aggregation measures 
make no supposition about the cause of such 
aggregation, and recurrence risks within the same 
generation, such as sibling risk ratios, will identify both 
shared environmental and genetic eﬀ ects. In infectious 
diseases, transmission of pathogens between family 
members may increase the risk of disease and contribute 
to the observed phenotypic aggregation. For example, 
in a study of sibling recurrence risk ratio for 
meningococcal disease, there was a 30 times  increased 
risk of infection in siblings of cases compared with the 
general population risk, but the risk decreased with a 
longer time interval between the index case and the 
sibling case.22 The recurrence risk for meningococcal 
disease in siblings was 11·9 times the population risk 
when the index and sibling cases occurred more than a 
week apart, falling to a risk of 8·2 if a year had elapsed 
between cases.22 These data indicate signiﬁ cant genetic 
determinants of meningococcal susceptibility, and also 
the importance of common acquisition of virulent 
strains within families, which accounts for the more 
immediate increased risk in household contacts.23 
Twin studies
Studies of twins can also provide an estimate of the 
relative contributions of shared genes and environment 
to disease phenotypes, by comparing the risk in 
genetically identical monozygotic twin pairs to that in 
dizygotic twins, who share on average only half their 
genes. Some twin studies of infectious diseases are 
historical,24–26 and determinations of zygosity and disease 
phenotype may be inaccurate.25 Notwithstanding these 
reservations, susceptibility to some infections show 
markedly increased concordance in monozygotic 
compared with dizygotic twins.27 Examples include 
tuberculosis,24–26 sinusitis,28 Helicobacter pylori-speciﬁ c 
antibody titres,29 and leprosy.30 More recent twin and 
triplet data indicate that susceptibility to both acute and 
chronic otitis media is largely genetically determined.31,32 
The relative contributions of infection, atopy, and cranio-
facial anatomy, all of which are determined in part by 
genetic factors, remain unclear.
Twin studies may also provide useful insights into the 
determinants of disease outcome. Carrier status for 
hepatitis B virus33 and the febrile response to (but not 
acquisition of) Plasmodium falciparum34 both indicate 
increased concordance in monozygotic twin pairs. A 
study of the severity of common childhood infections, 
which used hospital admission as the phenotype, 
indicated that distinct genetic factors were likely to be 
involved in diﬀ erent infections, since the risk of 
admission in the second twin was only increased if the 
twins both had the same infectious diagnosis 
(Burgner D, unpublished). The concordance rates for 
common otolaryngological procedures such as 
myringotomy and adeno-tonsillectomy, which are 
surrogates for disease severity, also show greatly increased 
concordance in monozygotic twin pairs (Burgner D, 
unpublished). Twin studies of vaccine responses, in 
which the antigenic stimulus is unambiguous, indicate 
signiﬁ cant genetic inﬂ uences on both humoral35 and cell-
mediated36 responses. More detailed genetic studies 
indicate the importance of both HLA and non-HLA loci 
in vaccine responsiveness.37,38 Studies in vitro of twins39 
and ﬁ rst-degree relatives40 also show the importance of 
genetic factors in determining the innate immune 
responses to infectious stimuli.
A twin study of H pylori acquisition, which compared 
concordance rates for twins reared either together or 
apart, gave very similar measures of genetic inﬂ uences 
in each setting, which accounted for most of the disease 
risk.29 However, twins and siblings are very commonly 
reared together, making it diﬃ  cult to tease out the 
relative contributions of genetic factors and shared 
environ mental exposures, particularly pathogen 
sharing. Intergenerational studies may circumvent this 
issue. A seminal study compared the risk and shared 
causes of premature mortality in children adopted very 
early in life with that of their biological and adoptive 
parents.41 The risk of an adopted child dying of infection 
was increased almost six times if their biological parent 
had also died prematurely of infection, whereas no 
increased risk was observed if the adoptive parent died 
of infection, suggesting that genetic rather than 
environmental factors are the important determinants 
of infectious disease mortality. Much smaller genetic 
eﬀ ects were noted for cardiovascular disease and 
malignancy.41
Study design and methodological issues
These epidemiological data indicate that genetic factors 
inﬂ uence both susceptibility to, and outcome of, 
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infection. The various study designs and methodological 
issues are important in interpreting previous data and in 
designing contemporary and future studies in infection. 
As the fundamentals of genetic epidemiology have 
recently been reviewed in detail,42–48 only a brief overview 
will be provided here. Some of the terminology is 
explained brieﬂ y in the panel. Of note, although single 
nucleotide polymorphisms (SNPs) are the workhorse of 
current high-throughput genotyping technologies, other 
forms of genetic variation are also common in the human 
genome and may have important eﬀ ects on disease risk. 
These include repeating sequence motifs (microsatellites 
and minisatellites), insertions and deletions, and 
diﬀ erences in gene copy number.55 For example, recent 
data indicate that there is a strong inverse correlation 
between the number of copies of an HIV suppressive 
chemokine gene (CCL3L1) and HIV susceptibility.56
Genome-wide linkage and association studies
There are essentially two types of study design—genome-
wide and candidate gene—that are used to localise the 
genes underlying human disease. Genome-wide studies 
have the advantage that no supposition is made about the 
genes involved, and potentially novel or unconsidered 
genes may be identiﬁ ed. Typically, the genome-wide 
approach has used linkage studies of multiply aﬀ ected 
(or infected) pedigrees to identify regions of the entire 
genome that are transmitted from the parents to the 
oﬀ spring more often than expected under independent 
inheritance.43 Typically, aﬀ ected sibling pairs,57,58 or larger 
multicase pedigrees59 if available, are recruited and the 
inherited regions of the genome are deﬁ ned by a few 
hundred microsatellite markers. The main disadvantages 
of linkage studies are that suﬃ  cient numbers of aﬀ ected 
sibling pairs may be diﬃ  cult to recruit for many 
infections, and that linkage studies are often too 
insensitive to pick up the relatively small contributions 
from individual genetic regions that are typical of 
complex diseases such as infection. There are examples 
of successful genome scans undertaken using linkage 
analysis for infectious diseases, including the intensity of 
infection with Schistosoma mansoni,59 susceptibility to 
H pylori,60 and to leprosy.57,58,61 As with association data, 
some linkage studies have not been replicated in diﬀ erent 
populations. In some cases this may represent a false 
discovery rate, an inherent problem in studies that make 
multiple statistical comparisons, but it is increasingly 
clear that many complex diseases show genetic 
heterogeneity, with diﬀ erent genetic determinants for 
the same disease operating in diﬀ erent ethnic groups. 
For example, mutations in the NOD2/CARD15 locus, an 
important susceptibility determinant of inﬂ ammatory 
bowel disease in white populations, are eﬀ ectively absent 
in Asian populations with the same phenotype.62
Genome-wide association studies, in which the whole 
genome is interrogated using hundreds of thousands of 
SNPs, have recently become a reality as genotyping 
technology and analytical tools evolve. This approach will 
potentially detect more subtle genetic eﬀ ects than a 
classic linkage study.63 At present, studies use up to 
0·5 million of the approximately 11 million estimated 
SNPs in the human genome, but there are unresolved 
Panel: Deﬁ nitions for genetic terminology 
Allelic association
Statistical analysis to determine whether disease is associated with particular allelic 
variants at one or more loci, usually by comparing marker allele frequencies between a 
disease group and a control group.
FST statistic
A statistic to describe individuals, subpopulations, and whole population structures. Used 
to assess evidence for selection by comparing the frequency of an allele in diﬀ erent 
populations.49
Haplotype
A combination of marker alleles at diﬀ erent markers along the same chromosome that 
tend to be inherited as a unit.
Haplotype tag 
An SNP that acts as a deﬁ ning marker for a haplotype by virtue of linkage disequilibrium. 
Analysing haplotype tags, rather than all the variants on a haplotype, reduces redundancy 
and genotyping costs.
Heterozygosity
A measure of genetic diversity within a population.
Linkage analysis
Statistical analysis to localise genes and markers with respect to each other in the 
genome, based on recombination frequency. Linkage analysis can also be used to map a 
disease phenotype in relation to polymorphic markers.
Linkage disequilibrium
The non-random association of alleles at two or more neighbouring loci that are inherited 
together more often than expected by chance, providing the basis to haplotypes and 
linkage disequilibrium mapping. This association can potentially derive from population 
admixture.
Microsatellite
A polymorphism characterised by a variable number of tandem repeats, often deﬁ ned by 
the numbers of repeats in a row of at least two or more nucleotides. They are useful 
markers for family linkage studies and determining a person’s unique DNA ﬁ ngerprint in 
forensic medicine. Also known as SSR (simple sequence repeat) or STR (simple tandem 
repeat).
Population admixture
The recent combination of two or more previously distinct populations. Unknown 
admixture may result in spurious genetic associations in a case-control study design.
SNP
Single nucleotide polymorphism, single base-pair change at a speciﬁ c point in the 
genome.
SNP chip
Array technology that allows large numbers (up to a million) of SNPs to be genotyped on 
a single array typically the size of a microscope slide (eg, Aﬀ ymetrix50 or Illumina51) 
Additional useful references: Burton et al,42 Malats and Calafell,52,53 and Calafell and Malats.54
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issues particularly relating to the optimum density and 
location for these SNP markers (gene-centric or evenly 
spaced through the genome), which have implications 
for how much of the genome such studies truly cover,45 
as well as concerns regarding sample size and power.64 
Genome-wide association studies have a high false 
discovery rate, and replication in independent populations 
is essential. There are currently no reported genome-
wide association studies in infectious diseases, although 
such studies are underway. In particular, studies being 
undertaken under the banner of the Wellcome Trust 
Case-Control Consortium will look at up to 2000 cases 
and 3000 controls for eight complex diseases, including 
tuberculosis and malaria.65 For these two important 
infectious diseases, a two-stage strategy is proposed in 
which a 750 000 SNP chip (panel) will be used to genotype 
1000 cases and 1000 controls, and regions positive at 
p=0·1 followed up in at least another 1000 cases and 
1000 controls. This is one of the biggest projects ever 
undertaken to identify the genetic variations that may 
predispose people to, or protect them from, complex 
diseases. The hope is that by identifying these genetic 
signposts, researchers will be able to understand which 
people are most at risk, and also produce more eﬀ ective 
treatments.
The genome-wide association approach has been used 
on a smaller scale in other non-infectious genetically 
complex diseases. For example, genotyping of almost 
93 000 SNPs across the genome has identiﬁ ed a region of 
chromosome 6 associated with myocardial infarction. 
Further mapping identiﬁ ed a novel functional 
polymorphism in the lymphotoxin alpha (LTA) gene 
within this region and related functional variants in a 
ligand of LTA.66,67 The odds ratio associated with the LTA 
mutation was 1·78,67 an order of magnitude expected for 
a complex disease. In another study, a 120 000 SNP chip 
was used to compare 96 cases of age-related macular 
degeneration with 50 controls to identify a major gene 
(complement factor H) that determines susceptibility.68 A 
common intronic SNP among the 120 000 SNPs 
genotyped was strongly associated with disease, with a 
nominal p value of less than 10–7 (after correction for 
multiple testing), and a genotype relative risk for 
homozygous individuals of 7·4 (95% CI 2·9–19·0). Re-
sequencing revealed a polymorphism in linkage 
disequilibrium with the risk allele that caused a tyrosine 
to histidine change at amino acid 402 in the complement 
factor H protein. The numbers of cases and controls 
studied was small, increasing the possibility of a false 
positive result (although the relative risk was high 
compared with our usual expectation for complex 
diseases). Importantly, the SNP-chip study was 
immediately supported by two studies using four 
independent case-control populations.69,70 
These studies provide a major conceptual 
breakthrough in terms of the approaches that can be 
made with novel technologies, now more feasible with 
the recent publication of the phase I HapMap,71 and the 
data for phase II released in 2005 (http://www.hapmap.
org). The main practical objective of the HapMap 
project was to identify sets of SNPs that are in linkage 
disequilibrium with each other, so that a subset of these 
can be genotyped as so-called haplotype-tagging SNPs 
in a genome-wide association study, thus reducing the 
overall amount of genotyping required. The phase I 
data involved the genotyping of 1 million SNPs in 
unrelated individuals or parent/child trios of Nigerian, 
European, Chinese, and Japanese descent. Phase II 
extends this to 3·5 million SNPs. The phase I data has 
already provided many predictions and tests of 
applicability of haplotype tagging across populations,72,73 
optimum sampling and two-stage testing strategies for 
whole genome association studies,74 and which 
commercially available SNP chips will work best. As 
predicted from previous studies, a greater density of 
SNPs on a chip is required to capture all the haplotypic 
diversity in the African population compared with 
European, Chinese, or Japanese populations, because 
of the greater diversity and shorter regions of linkage 
disequilibrium observed in the former,75 a factor that 
will be important in application of the technology to 
infectious disease association studies in Africa. 
Nevertheless, for 1000 cases and 1000 controls and a 
nominal p value of 0·01, the phase I HapMap (eg, the 
newly released Sentrix human Hap300 genotyping 
beadchip by Illimuna;51 one SNP about every 12 kb) 
retains 77% power to detect associations due to common 
(≥5%) causal alleles in the African population, compared 
with roughly 90% in European, Chinese, or Japanese 
populations.75 The 500 000 SNP chip from Aﬀ ymetrix,50 
which was made before the release of phase I HapMap 
haplotype-tagging SNP information, has about the 
same power as the Illumina human Hap300 chip (ie, it 
contains about two tags per haplotype).
Candidate gene approach
Although there will probably be many whole genome 
association studies in the future, to date most studies of 
complex diseases, including infection, have adopted a 
candidate gene approach. The choice of the candidate 
genes may come from animal data,76,77 results of whole-
genome studies,57,58,78 clinical data,79,80 or simply biological 
plausibility. Important methodological considerations in 
this approach include the following: (1) an adequate 
density of the markers in the candidate gene to ensure 
that the study has suﬃ  cient sensitivity to exclude a 
genetic region; (2) narrow and consistent phenotypic 
deﬁ nitions; (3) matching of cases and controls; and (4) 
sample size and power. 
Most candidate gene studies use a case-control 
approach, and unrecognised ethnic diﬀ erences between 
the groups will probably result in spurious genetic 
associations that are unrelated to the disease of interest. 
For example, there is probably a strong association 
http://infection.thelancet.com   Vol 6   October 2006 657
Review
between the HLA region and chopstick use in Sydney. 
This does not imply that the HLA region necessarily 
inﬂ uences manual dexterity, but more likely that the 
HLA type identiﬁ es an Asian subpopulation. This issue 
of population stratiﬁ cation is likely to be more 
confounded when small genetic eﬀ ects are sought in 
large populations.81 However, this confounding can be 
minimised if cases and controls are carefully matched. 
The presence of genetic admixture can also be quantiﬁ ed 
from the genetic data itself,82 allowing stratiﬁ ed analyses 
if the sample size permits. In paediatric populations, an 
alternative approach is to use the parents as the genetic 
controls for their aﬀ ected oﬀ spring.83 This approach is 
intrinsically less powerful than case-control designs, 
since the parental controls are enriched for the genetic 
variants of interest, but it allows inclusion of families of 
mixed ethnicity and potential pooling of data across 
ethnic groups, if signiﬁ cant genetic heterogeneity is not 
present.
Probably the most crucial and overlooked 
methodological issue is sample size and power. Because 
the genetic eﬀ ects from individual genetic variants are 
usually modest, the genetic model (mode of inheritance) 
is often unknown, and the frequency of the disease-
modifying variant may vary, almost all studies of complex 
disease genetics to date have been underpowered. Power 
calculations (ﬁ gure) indicate that in excess of 1500 case-
control pairs or case-parent trios are needed to provide 
adequate power, especially as eﬀ ect sizes (odds ratios) 
expected for a genetic contribution to complex disease 
susceptibility will probably be small (about 1·5). 
The lack of power owing to small sample sizes makes 
it diﬃ  cult to interpret current and previous data on 
genetic susceptibility to infection. For this reason we 
have not attempted a critical appraisal or value judgment 
of past and present studies, but have provided 
comprehensive tables (webtables 1, 2, 3 and 4) that list 
all of the studies undertaken to date for the most 
commonly studied infectious diseases—HIV, 
mycobacterial infections (leprosy and tuberculosis), 
malaria, and leishmaniasis. Whereas some loci (eg, 
HLA class I, class II, and class III alleles, SLC11A1) 
feature repeatedly both within and between diseases, 
no formal meta-analyses86 of these smaller studies have 
yet been undertaken to determine which may indicate 
statistically reliable associations. One interesting 
observation is the number of candidate gene studies 
that have focused on proteins involved in innate 
recognition of microbes and ﬁ rst-line defence innate 
immunity pathways (table 1), underscoring the likely 
selective pressures that have been exerted by infectious 
diseases. The key genes that regulate acquired immune 
responses also feature as candidate genes in multiple 
infectious diseases (table 2).
Most of these studies also suﬀ er from a lack of statistical 
power, and require replication and validation. of these 
immune response genes are highly polymorphic or 
clustered, or both, in the genome, which is an indication of 
evolutionary pressure and selection.166,167 A more formal 
attempt to search for signals of evolutionary selection was 
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Figure: Power to detect allelic association for a risk allele having an eﬀ ect size 
(odds ratio) of 1·5 
(A) 500, (B) 1500, and (C) 3000 trios or case-control pairs. Power is calculated 
for diﬀ erent frequencies of risk alleles, and for samples of 500, 1500, or 
3000 trios or case-control pairs. Power approximations for trios by a standard 
transmission disequilibrium test84 have been made using the method of Knapp.85 
Theoretical power to detect allelic association was made assuming a 
multiplicative model. Results are given as a ﬁ rst approximation of the 
percentage power to detect allelic association at p=0·01, p=0·001, or p=0·0001. 
Power calculations were essentially identical for a similar size case-control 
sample. The advantage of trios is that they are not inﬂ uenced by population 
admixture. The advantage of case-control analysis is one third less genotyping 
to obtain equivalent power. The graphs show that 500 trios or case-control pairs 
have very poor power to detect allelic association even for relatively common 
risk alleles (frequencies >0·2). A sample of 1500 trios or case-control pairs has 
good power for risk alleles at frequencies >0·1. A sample of 3000 trios or case-
control pairs improves power for rare risk alleles (frequencies <0·1). 
See Online for webtables 1,2,3 
and 4.
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recently undertaken in 168 genes related to immune 
function.3 Almost 1700 common SNPs were successfully 
genotyped across these genes in three population samples: 
96 independent chromosomes from Utah residents with 
European ancestry, 120 from Han Chinese Guangxi, and 
124 from the Yoruba people of Southwest Nigeria (these 
samples were overlapping but not identical to those used 
in the HapMap project).  Evidence for selection was based 
on four tests of non-neutral evolution: (1) assessment of 
the percentage of SNPs within a locus with low (<10%) 
minor allele frequency and the percentage with high 
(>40%) minor allele frequency; (2) assessment of the 
frequency of derived (non-ancestral) alleles; (3) comparison 
of FST (panel) versus heterozygosity; and (4) relative 
extended haplotype homozygosity. In tests of allele 
frequency, three of the 168 genes stood out: IL9, FUT2, and 
CAV2. IL9 lies in the cluster of T-helper-2 related genes 
encoding interleukins 4, 5, 9, and 13 on chromosome 5q31-
q33, which has been implicated in many infectious disease 
studies (table 2; webtables 1–4). FUT2 encodes a protein 
responsible for determining ABO blood protein secretor 
status, and variation in this gene may protect against 
respiratory pathogens,168 H pylori,169 and HIV-1.170 CAV2 
encodes one of the caveolin proteins that function as 
scaﬀ olding structures in cholesterol-rich lipid rafts, which 
enhance immune cell function,168,171 and are involved in 
pathogen entry into host cells.172 The relative extended 
haplotype homozygosity test provided the best evidence for 
selection, highlighting ABCC1 (or multidrug resistance 
protein MRP1, implicated in resistance to Streptococcus 
pneumoniae in mice173), APCS (serum amyloid P 
component), and VAV3 (a guanine nucleotide exchange 
factor expressed in haematopoietic and other cells, recently 
identiﬁ ed as a gene for type I diabetes in mice174) as genes 
with signatures of past selection. Although Walsh and 
colleagues3 discuss the limitations of their study and the 
need for validation, their research pilots the search for 
signatures of evolutionary selection that can now be 
Gene Function Infectious disease associations*
HLA class I Presentation of antigen to CD8 T cells HIV, tuberculosis, leprosy, malaria, leishmaniasis
HLA class II Presentation of antigen to CD4 T cells HIV, hepatitis C,149 tuberculosis, leprosy, malaria, 
leishmaniasis 
IL4/IL13 Cytokine product of T-helper 2 cells HIV, hepatitis C,150 respiratory syncytial virus,151,152 
H pylori,153 candidiasis,154 malaria, leishmaniasis, 
schistosomiasis155
IFNG† Cytokine product of T-helper 1 cells HIV, hepatitis B,156 Epstein-Barr virus,157 respiratory 
syncytial virus,158,159 H pylori,95 brucellosis,160 malaria, 
tuberculosis, leprosy, schistosomiasis161 
IFNGR1† Type 1 receptor for interferon γ on 
macrophages
Periodontitis,162 H pylori,163 atypical mycobacterial 
infection,164,165 tuberculosis, malaria, post-Kala-azar 
dermal leishmaniasis
*References given are only for disease associations not covered in webtables 1–4 that summarise candidate gene 
association studies for HIV, tuberculosis, leprosy, malaria, and leishmaniasis. References are not exhaustive, and 
generally provide examples of studies showing associations that have been published in the last 5 years. †Since natural 
killer cells make interferon γ, these genes could also be thought of as innate immunity genes.
Table 2: Examples of candidate genes related to acquired immunity that are associated with infectious 
disease susceptibility or outcome
Gene Function Infectious disease associations*
TNFA Pro-inﬂ ammatory cytokine HIV, hepatitis B,87 human papilloma virus,88,89 meningococcal meningitis,90,91 typhoid,92 
leprosy, tuberculosis, malaria, leishmaniasis, Helicobacter pylori93–95 
IL1A, IL1B Pro-inﬂ ammatory cytokine HIV, hepatitis C,96 meningococcal meningitis,97 H pylori,98–100 periodontitis,101,102 tuberculosis, 
malaria
IL10 Anti-inﬂ ammatory cytokine HIV, Epstein-Barr virus,103,104 herpes zoster virus,105 cytomegalovirus,106 hepatitis B and C,107 
H pylori,95,99 meningococcal meningitis,91,108 pneumonia109 and pneumococcal septic shock,110 
tuberculosis, leprosy
NOS2A Inducible nitric oxide synthase producing toxic 
nitrogen radicals
Hepatitis C,111 brucellosis,112 tuberculosis, malaria
FcγRIIA† Activating Fc receptor promoting 
pro-inﬂ ammatory response
HIV, severe acute respiratory syndrome-associated coronavirus,113 dengue haemorrhagic 
fever,114 otitis media,115 Streptococcus pneumoniae,116 rheumatic fever (streptococcus),117 
periodontitis,118–121 meningococcal meningitis and sepsis,108,122,123 malaria
FcγRIIB† De-activating Fc receptor down regulating 
pro-inﬂ ammatory response
Periodontitis,124 malaria
SLC11A1 Proton-coupled divalent cation transporter with 
multiple pleiotropic eﬀ ects on macrophage function
HIV, hepatitis C,125 leprosy, tuberculosis, Buruli ulcer (Mycobacterium ulcerans),126 Kawasaki 
disease,127 visceral leishmaniasis
MBP (MBL) Mannose binding lectin opsonises for complement 
activation by classic pathway
HIV, hepatitis B,128,129 severe acute respiratory syndrome-associated coronavirus,130 Gram  
negative and positive bacterial infection,131 Kawasaki disease,132 Chlamydia pneumoniae,133 
meningococcal meningitis,134 aspergillosis,135 candidiasis,136 tuberculosis, malaria, ﬁ lariasis137
TLR2/TLR4 Toll receptors 2 and 4;138 pattern recognition 
receptor for lipopolysaccharide and lipoproteins on 
bacteria and mycobacteria
Respiratory syncytial virus,139 meninogoccal meningitis,122,140 Lyme disease (Borrelia 
bergdorferi),141 staphylococcal infection,142 periodontitis,143 Boutonneuse fever,144 Gram 
negative145,146 and positive131 bacterial infection, brucellosis,147 Legionnaires’ disease,148 
tuberculosis, leprosy, malaria
*References given are only for disease associations not covered in webtables 1–4 that summarise candidate gene association studies for HIV, tuberculosis, leprosy, malaria, 
and leishmaniasis. References are not exhaustive, and generally provide examples of studies showing associations that have been published in the last 5 years. †These two 
genes are closely linked and are usually in linkage disequilibrium with each other, making it unclear which of these loci is the disease-associated gene.
Table 1: Examples of candidate genes related to innate immunity that are associated with infectious disease susceptibility or outcome
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undertaken in HapMap-style data, providing a real 
opportunity to identify the genes that have been under the 
strongest evolutionary pressure from infectious diseases. 
The advent of all these new technologies and tools oﬀ er 
exciting prospects for future research, allowing us to return 
to the drawing board in studying human genetic 
susceptibility to infectious disease. In so doing, it will be 
interesting to see how many of the candidate gene studies 
undertaken to date (webtables 1–4) are supported by 
potentially more powerful genome-wide association 
studies. Although a case can also be made for simply 
increasing sample size and power even with a more 
directed candidate gene approach, it is debatable whether 
the genes that show signiﬁ cant evidence of selection would 
have been readily chosen as obvious candidate loci. Thus, a 
combination of genome-wide, candidate gene, and other 
approaches may ultimately prove the most rewarding.
Gene–gene and gene–environment interactions
Genetic determinants obviously act in a genetic and 
environmental context, a fact often ignored in genetic 
epidemiological studies that have previously regarded the 
environment as something of an annoyance. A genetic 
variant may substantially increase the risk of avian 
inﬂ uenza several hundred times, but if the person 
carrying the variant never encounters H5N1 inﬂ uenza, or 
requires an additional polymorphism in a diﬀ erent gene 
to have a functional eﬀ ect, then this ﬁ rst variant may be of 
no clinical relevance. The ﬁ eld of genetic epidemiology is 
increasingly acknowledging the importance of complex 
biological interactions in understanding genetic 
determinants. Gene–gene interactions (epistasis) have 
been described for HIV infection, in which an HLA class I 
allele is associated with more rapid progression to AIDS 
only when an individual also carries a speciﬁ c natural 
killer cell (KIR) receptor.175 Gene–environment interactions 
have been shown in spontaneous preterm labour, which 
has an inﬂ ammatory basis. Although genetic variation at 
the tumour necrosis factor (TNFA) gene is associated 
with increased risk of preterm labour, this risk is increased 
signiﬁ cantly in the presence of bacterial vaginosis, itself 
an independent risk for the same outcome.176 In cystic 
ﬁ brosis, those carrying functional variants of mannose-
binding lectin (MBL) have worse pulmonary outcomes,177 
and replacement MBL therapy has been reported in MBL-
deﬁ cient cystic ﬁ brosis patients.178 Not surprisingly, MBL 
exerts a protective eﬀ ect through its innate immunological 
eﬀ ects and in a recent small study, MBL deﬁ ciency only 
aﬀ ected lung function when associated with Staphylococcus 
aureus colonisation,179 an example of a gene–enviroment 
interaction. 
Conclusion: translation of genetic data into 
therapeutic interventions
Despite an increasing body of robust data identifying 
genetic determinants of infectious diseases and 
illuminating key biological pathways, the move from 
bench to bedside in infectious diseases and other ﬁ elds 
remains largely an unrealised, but often made, 
prediction. There are a few worthy exceptions. Functional 
genetic variation of the P450 cytochrome system seems 
to mediate the eﬃ  cacy of H pylori eradication by its 
eﬀ ects on proton pump inhibitor metabolism.180 The 
most striking and elegant example of pharmacogenetics 
is in HIV medicine, in which hypersensitivity to the 
nucleoside reverse transcriptase inhibitor abacavir has 
previously limited its use. Analysis of the MHC led to 
the identiﬁ cation of a particular HLA haplotype that 
greatly increased the risk of abacavir hypersensitivity,181 
and further mapping localised a functional variant in 
the peptide-binding groove of heat shock protein 70, 
which lies in the central MHC.182 Genotyping individuals 
for this variant before commencing abacavir is cost 
eﬀ ective.183 Hopefully, further examples of clinically 
relevant pharmacogenetics in infectious diseases will be 
reported. In the face of increasing antimicrobial 
resistance, falling pharmaceutical enthusiasm for new 
antibiotic development, and the disappointing track 
record of adjunct biological therapies in severe sepsis, 
the development of novel vaccines and pharmacogenetic 
interventions remain among the most important goals 
for genetic studies of infectious disease susceptibility.
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